UB Paderborn / Katalog / Suche / in CDI

Telaprevir for Retreatment of HCV Infection

The New England journal of medicine, 2011-06, Vol.364 (25), p.2417-2428

2011

Link zum Volltext

Verfügbarkeit prüfen

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

The New England journal of medicine, 2011-06, Vol.364 (25), p.2405-2416

2011

Link zum Volltext

Verfügbarkeit prüfen

Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: A multicenter prospective study

Journal of hepatology, 2015-05, Vol.62 (5), p.1056-1060

2015

Link zum Volltext

Verfügbarkeit prüfen

Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study

Liver international, 2009-03, Vol.29 (3), p.415-419

2009

Link zum Volltext

Verfügbarkeit prüfen

Use of albumin in the treatment of cirrhosis: introduction

Annals of hepatology, 2011, Vol.10 Suppl 1, p.S5-S5

Terg, Ruben

2011

Link zum Volltext

Verfügbarkeit prüfen

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C

Journal of hepatology, 2014-12, Vol.61 (6), p.1220-1227

2014

Link zum Volltext

Verfügbarkeit prüfen

Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy

Gastroenterology (New York, N.Y. 1943), 2009-05, Vol.136 (5), p.1618-1628.e2

2009

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study

Journal of hepatology, 2002-12, Vol.37 (6), p.717-722

2002

Link zum Volltext

Verfügbarkeit prüfen

Large-Volume Paracentesis: Which Plasma Expander?

Ascites, Hyponatremia and Hepatorenal Syndrome: Progress in Treatment, 2010, Vol.28, p.32-39

2010

Link zum Volltext

Verfügbarkeit prüfen

Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C

Gastroenterology (New York, N.Y. 1943), 2011-06, Vol.140 (7), p.1990-1999

2011

Link zum Volltext

Verfügbarkeit prüfen

Variceal band ligation and variceal band ligation plus sclerotherapy in the prevention of recurrent variceal bleeding in cirrhotic patients: a randomized, prospective and controlled trial

Gastrointestinal endoscopy, 2000-02, Vol.51 (2), p.157-163

2000

Link zum Volltext

Verfügbarkeit prüfen

Spontaneous bacterial peritonitis and pharmacologic acid suppression in patients with cirrhosis

Hepatology (Baltimore, Md.), 2013-01, Vol.57 (1), p.411-413

2013

Link zum Volltext

Verfügbarkeit prüfen

Primary biliary cirrhosis and hepatocellular carcinoma

Autoimmunity reviews, 2002-08, Vol.1 (4), p.220-225

2002

Link zum Volltext

Verfügbarkeit prüfen

Clinical trial: short‐term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, double‐blind, placebo‐controlled study

Alimentary pharmacology & therapeutics, 2010-04, Vol.31 (8), p.834-845

2010

Link zum Volltext

Verfügbarkeit prüfen

M1267 Increased Intestinal Permeability (IP) in Cirrhosis is Associated to the Severity of the Liver Disease and a Higher Mortality

Gastroenterology (New York, N.Y. 1943), 2010, Vol.138 (5), p.S-367-S-367

2010

Link zum Volltext

Verfügbarkeit prüfen

Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: A randomized, placebo-controlled study

Journal of hepatology, 2008-05, Vol.48 (5), p.774-779

2008

Link zum Volltext

Verfügbarkeit prüfen

Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study

Hepatology (Baltimore, Md.), 2003-02, Vol.37 (2), p.359-365

2003

Link zum Volltext

Verfügbarkeit prüfen

Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study

Journal of hepatology, 2000-10, Vol.33 (4), p.564-569

2000

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis and the risk of developing malignancies. A large prospective study

Acta gastroenterologica latinoamericana, 2008-03, Vol.38 (1), p.26-33

2008

Link zum Volltext

Verfügbarkeit prüfen

Splenic hypofunction in cirrhosis is not associated with increased risk for infections

European journal of gastroenterology & hepatology, 1996-03, Vol.8 (3), p.257-260

1996

Link zum Volltext

Verfügbarkeit prüfen

831 FibroTest (Ft) Baseline Value Is An Independent Predictor of Early (EVR) and Sustained Virological Response (SVR) in Non-Responders Patients Re-Treated with Pegylated Interferon Alfa-2B (PEG-2B) and Ribavirin in EPIC3

Gastroenterology (New York, N.Y. 1943), 2009-05, Vol.136 (5), p.A-809-A-809

2009

Link zum Volltext

Verfügbarkeit prüfen

295 Final Results of the EPIC3 Cirrhosis Maintenance Trial: Pegintron Maintenance Therapy in Cirrhotic (METAVIR F4) HCV Patients, Who Failed to Respond to Interferon/Ribavirn (IR) Therapy

Gastroenterology (New York, N.Y. 1943), 2009-05, Vol.136 (5), p.A-798-A-798

2009

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Telaprevir for Retreatment of HCV Infection

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: A multicenter prospective study

Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study

Use of albumin in the treatment of cirrhosis: introduction

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C

Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy

Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study

Large-Volume Paracentesis: Which Plasma Expander?

Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C

Variceal band ligation and variceal band ligation plus sclerotherapy in the prevention of recurrent variceal bleeding in cirrhotic patients: a randomized, prospective and controlled trial

Spontaneous bacterial peritonitis and pharmacologic acid suppression in patients with cirrhosis

Primary biliary cirrhosis and hepatocellular carcinoma

Clinical trial: short‐term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, double‐blind, placebo‐controlled study

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program

Corrigendum to: “FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program” [J Hepatol 2011;54:227–235]

M1267 Increased Intestinal Permeability (IP) in Cirrhosis is Associated to the Severity of the Liver Disease and a Higher Mortality

Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: A randomized, placebo-controlled study

Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study

Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study

Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis and the risk of developing malignancies. A large prospective study

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC 3 program

Splenic hypofunction in cirrhosis is not associated with increased risk for infections

831 FibroTest (Ft) Baseline Value Is An Independent Predictor of Early (EVR) and Sustained Virological Response (SVR) in Non-Responders Patients Re-Treated with Pegylated Interferon Alfa-2B (PEG-2B) and Ribavirin in EPIC3

295 Final Results of the EPIC3 Cirrhosis Maintenance Trial: Pegintron Maintenance Therapy in Cirrhotic (METAVIR F4) HCV Patients, Who Failed to Respond to Interferon/Ribavirn (IR) Therapy

Suchergebnisse filtern